Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Lupin has informed that the Company has voluntarily recalling its Metformin Hydrochloride Extended- Release Tablets USP, 500mg and 1000mg products in the US. This recall is being conducted out of an abundance of caution in line with the ongoing interaction with the US Food and Drug Administration on NDMA impurity levels. The associated press release in the US is enclosed for reference.
The above information is a part of company’s filings submitted to BSE.
